TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27393505
Drug: para-toluenesulfonamide (PTS)
Normalized name: o-toluenesulfonamide
DrugBank: p-Toluenesulfonamide (DB17299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: para-toluenesulfonamide (PTS) intratumoral injection
Study: 20942940
Drug: Erythropoietin (Epo)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (Epo) 40,000 IU weekly infusions for 8 weeks
Study: 20942940
Drug: Saline (NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (NaCl 0.9%) weekly infusions for 8 weeks
Study: 16803917
Drug: Subarachnoid block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid block (SAB) with bupivacaine, clonidine, and morphine
Study: 10875189
Drug: Progressive relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive relaxation (PR) treatment for insomnia
Study: 9663828
Drug: Budesonide 3
Normalized name: budesonide 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 3 mg t.d.s. for 6 months
Study: 3947124
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% minoxidil solution
Study: 25204509
Drug: Landiolol 2
Normalized name: Landiolol 280 MG Intravenous Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol 2 μg/kg/min (Group L2)
Study: 25204509
Drug: Landiolol 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol 5 μg/kg/min (Group L5)
Study: 24067398
Drug: Dexpramipexole 150
Normalized name: Dexpramipexole
DrugBank: Dexpramipexole (DB15130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexpramipexole 150 mg twice daily
Study: 10917405
Drug: Codeine 180
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine 180 mg
Study: 10917405
Drug: Quinidine single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine single-dose (50 mg)
Study: 10917405
Drug: Quinidine short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine short-term (50 mg four times a day for 4 days)
Study: 8768938
Drug: Risperidone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2 < max <= 5 mg)
Study: 8768938
Drug: Risperidone (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (higher than 15 mg)
Study: 8768938
Drug: Risperidone (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (higher than 10 mg)
Study: 1348750
Drug: Immediate intravenous
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate intravenous beta‐adrenergic blocking agent therapy
Study: 1348750
Drug: Deferred beta‐blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred beta‐blocker therapy
Study: 2940091
Drug: beta-adrenoceptor blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-adrenoceptor blocker metoprolol (n = 88)
Study: 2940091
Drug: thiazide diuretic
Normalized name: Thiazide diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: thiazide diuretic hydrochlorothiazide (n = 80)
Study: 27554670
Drug: 1250 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 mg/day omega-3 fatty acid + alpha-tocopherol placebo
Study: 27554670
Drug: 1250 mg
Normalized name: bran 1250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 mg omega-3 fatty acids/day + 400 IU/day alpha-tocopherol
Study: 9509213
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (Group A)
Study: 24647296
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose (Group B)
Study: 24647296
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EMLA cream and oral sucrose (Group C)
Study: 22590998
Drug: Vaginal preparation
Normalized name: Trichomonas vaginalis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal preparation with povidone-iodine solution
Study: 22590998
Drug: No vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vaginal preparation (control)
Study: 20217116
Drug: Sodium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium intake reduced to approximately 1,500 mg/day
Study: 20217116
Drug: Habitual sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habitual sodium intake of approximately 3,000 mg/day
Study: 18555934
Drug: Doripenem 500
Normalized name: doripenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doripenem 500 mg IV q8h
Study: 18555934
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g IV q8h
Study: 7821474
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac 0.1% pretreatment
Study: 7821474
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no topical diclofenac)
Study: 31462310
Drug: Si-ni-tang (SNT)
Normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Si-ni-tang (SNT) 150 mL per day for 3 days
Study: 31462310
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 150 mL per day for 3 days
Study: 21901285
Drug: Sibutramine (pharmacotherapy)
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sibutramine (pharmacotherapy) for 1 year
Study: 21901285
Drug: BIB/pharmacotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIB/pharmacotherapy after BIB removal
Study: 21901285
Drug: BIB/lifestyle or
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIB/lifestyle or BIB/pharmacotherapy
Study: 21901285
Drug: Pharmacotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy group
Study: 19623780
Drug: Topical products
Normalized name: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical products designed to improve skin barrier function, hydration, and skin turnover
Study: 19623780
Drug: Topical products
Normalized name: TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical products
Study: 12142121
Drug: Salbutamol (Salb)
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol (Salb) 400 microg administered via inhalation after intravenous N‐omega‐nitro‐monomethyl‐L‐arginine (L‐NMMA) 3 mg/kg over 5 min
Study: 12142121
Drug: Salbutamol (Salb)
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol (Salb) 400 microg administered via inhalation after control solution (normal saline)
Study: 12142121
Drug: Salbutamol (Salb)
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol (Salb) after L‐NMMA
Study: 10547221
Drug: Intracoronary ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary ketanserin (1.5 mg in 10 ml normal saline administered over 3 min)
Study: 8703545
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy with doses ranging from 45 to 50 Gy in the compartmental volume after complete resection, and from 55 to 60 Gy in the tumor bed after marginal or incomplete resection.
Study: 526382
Drug: etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: etomidate 0.3 mg kg‐1 preceded by fentanyl 1.25 or 2.5 microgram kg‐1 i.v.
Study: 526382
Drug: etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: etomidate 0.3 mg kg‐1 preceded by diazepam 0.0625 or 0.125 mg kg‐1 i.v.
Study: 526382
Drug: etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: etomidate 0.3 mg kg‐1 preceded by fentanyl 2.5 microgram kg‐1 i.v.
Study: 27853925
Drug: Fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride gel applications with intensive dental prevention in kindergarten
Study: 27853925
Drug: Fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride gel applications without intensive dental prevention in kindergarten
Study: 27853925
Drug: Maximum group
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum group prevention (intensive prevention in kindergarten and gel program at school)
Study: 25868203
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil (FA) 1 mg x kg(‐1) administered at the end of surgery, n = 20
Study: 25868203
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no FA administration), n = 20
Study: 23601744
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg once daily (QD)
Study: 23601744
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg twice daily (BID)
Study: 23601744
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg BID
Study: 23601744
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg QD
Study: 23601744
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg QD
Study: 23601744
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg BID
Study: 19873917
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Cinnarizine, Cyproheptadine and Vitamin E
Study: 16625520
Drug: Experimental HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental HIV vaccine
Study: 9741369
Drug: Theophylline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (600 or 800 mg daily)
Study: 9741369
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of theophylline and ipratropium bromide
Study: 3195055
Drug: NIVGRIP trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIVGRIP trivalent inactivated influenza vaccine
Study: 29390493
Drug: Ping Chuan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ping Chuan Ke Li (PCKL) plus oral montelukast
Study: 29390493
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus oral montelukast
Study: 26188003
Drug: Sildenafil, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil, 60 mg three times a day for 12 weeks
Study: 17096718
Drug: HL-450 (0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL-450 (0.45 g/100 mL)
Study: 17096718
Drug: HL-350 (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL-350 (0.35 g/100 mL)
Study: 15543442
Drug: Standard Constraint‐Induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Constraint‐Induced Movement therapy (matched group of 12 subjects)
Study: 27859251
Drug: Paediatric fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paediatric fixed-dose combination (FDC) zidovudine/lamivudine/nevirapine (60/30/50 mg) tablet
Study: 26075487
Drug: Cariprazine 6-9
Normalized name: cariprazine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 6-9 mg/d
Study: 11036827
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil derived (n‐3) fatty acid supplementation (3‐6 capsules/day, 40 mg/kg body weight)
Study: 11036827
Drug: Olive/corn oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive/corn oil capsule supplement (control)
Study: 8847860
Drug: Spironolactone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (100 mg once daily for 1 week)
Study: 8847860
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 1 week)
Study: 3519142
Drug: Porcine intestinal
Normalized name: porcine intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine intestinal mucosa heparin
Study: 27466718
Drug: Isunakinra (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isunakinra (5 mg/mL)
Study: 27466718
Drug: Isunakinra (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isunakinra (20 mg/mL)
Study: 27466718
Drug: Isunakinra (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isunakinra (5 mg/mL) and (20 mg/mL)
Study: 26343102
Drug: Self-administered exercises
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered exercises based on Tuina techniques
Study: 23833362
Drug: Topical moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical moxifloxacin alone (Group-1): One drop 6 times/day for 3 days before surgery and one drop 4 times on the day of surgery
Study: 23833362
Drug: Topical moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical moxifloxacin with flurbiprofen (Group-2): One drop 6 times/day for 3 days before surgery and one drop 4 times on the day of surgery, plus flurbiprofen one drop 4 times/day for 3 days before and on the day of surgery
Study: 21912022
Drug: Cyclo 10
Normalized name: cyclo-D-Serine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclo 10 mg/kg monthly for six months then every two months for 12 months (Group I)
Study: 21912022
Drug: Cyclo 5
Normalized name: cyclo-D-Serine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclo 5 mg/kg monthly for six months then every two months for 36 months (Group II)
Study: 21912022
Drug: Cyclo 10
Normalized name: cyclo-D-Serine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclo 10 mg/kg (Group I)
Study: 21912022
Drug: Cyclo 5
Normalized name: cyclo-D-Serine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclo 5 mg/kg (Group II)
Study: 19167276
Drug: 200mg (E)-entacapone
Normalized name: entacapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg (E)-entacapone tablet formulation
Study: 16095445
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with remifentanil (1 microg kg‐1 remifentanil + 0.5 mg kg‐1 propofol)
Study: 16095445
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with alfentanil (10 microg kg‐1 alfentanil + 0.5 mg kg‐1 propofol)
Study: 16095445
Drug: Propofol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.75 mg kg‐1)
Study: 7810806
Drug: Total IgG
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total IgG antibodies
Study: 7810806
Drug: IgG4 antibodies
Normalized name: recombinant human IgG4 monoclonal antibody against FGF19
DrugBank: HH-009 (DB18727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG4 antibodies
Study: 7810806
Drug: IgG1 antibodies
Normalized name: Humanized monoclonal antibody HU3F8-IGG1
DrugBank: Naxitamab (DB15965)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IgG1 antibodies
Study: 7810806
Drug: IgG2 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG2 and IgG3 antibodies
Study: 3387717
Drug: Random walk
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random walk model applied to treatment groups
Study: 22101745
Drug: Pramipexole (PPX)
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pramipexole (PPX) 0.25-0.75 mg
Study: 22101745
Drug: Dual-release levodopa/benserazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-release levodopa/benserazide (L/B) 125-375 mg
Study: 22101745
Drug: Dual-release levodopa/benserazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-release levodopa/benserazide (L/B)
Study: 3651281
Drug: atracurium 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: atracurium 0.4 mg kg‐1
Study: 19196814
Drug: Inhaled beclometasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclometasone (200 microg day(‐1)) + Theophylline (400 mg day(‐1))
Study: 19196814
Drug: Theophylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (400 mg day(‐1))
Study: 19196814
Drug: Inhaled beclometasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclometasone (200 microg day(‐1))
Study: 15103566
Drug: Immunonutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunonutrition solution containing arginine, nucleotides, and polyunsaturated fatty acids
Study: 15103566
Drug: Isocaloric solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric solution
Study: 11339730
Drug: Intraosseous infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraosseous infusion using the bone injection gun (BIG)
Study: 9072603
Drug: Daily prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily prophylaxis (group 2, 65 patients)
Study: 9072603
Drug: Daily prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily prophylaxis (group 2)
Study: 7701881
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide cream (Microcid)
Study: 7701881
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid cream/gel (Fucidin)
Study: 3427696
Drug: Cefoxitin 2
Normalized name: cefoxitin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin 2 g IV every 8 hours
Study: 3427696
Drug: Cefotaxime 2
Normalized name: cefotaxime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 2 g IV every 8 hours
Study: 3427696
Drug: Moxalactam 2
Normalized name: Moxalactam
DrugBank: Moxalactam (hydrolyzed) (DB04740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam 2 g IV every 8 hours
Study: 3427696
Drug: Aztreonam 2
Normalized name: aztreonam 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam 2 g IV every 8 hours
Study: 31398135
Drug: Two-stage deployment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage deployment solution for PHEV power management applications
Study: 29540445
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) 2.4 g per day
Study: 26883688
Drug: fesoterodine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: fesoterodine with topical vaginal estrogen
Study: 19358990
Drug: Propofol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.25 mg/kg
Study: 10328274
Drug: Rectal-scalp temperature
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal-scalp temperature difference greater than 4 degrees C; Mean = 6.7, Range = 6.0-7.4; At the time of clinical brain death
Study: 10328274
Drug: Rectal-abdomen and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal-abdomen and rectal-mastoid temperature differences; No specific values reported
Study: 1566985
Drug: Sequential siting
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential siting in separate spaces
Study: 4051157
Drug: Oral dantrolene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dantrolene 1.5 mg/kg administered orally 4 hours pre-operatively
Study: 22776567
Drug: Optimized acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized acupuncture therapy
Study: 7986667
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg amlodipine racemate
Study: 2663318
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg ibuprofen
Study: 26414724
Drug: Placental matrix‐derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placental matrix‐derived mesenchymal stem cells (PM‐MSCs) injection
Study: 18510173
Drug: Oral Genetaxyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Genetaxyl at doses of 60 mg/m2, 120 mg/m2, and 180 mg/m2 with 10 mg/kg of oral cyclosporin A
Study: 18510173
Drug: Intravenous Genetaxyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Genetaxyl (175 mg/m2, 3-h infusion)
Study: 18510173
Drug: Intravenous Genaxyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Genaxyl (175 mg/m2, 3-h infusion)
Study: 18510173
Drug: Generic i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic i.v. paclitaxel (Genaxol, containing 50% CrEL; 175 mg/m2, 3-h infusion)
Study: 16585987
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily topical 1% pimecrolimus cream
Study: 16585987
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly narrowband UVB
Study: 16585987
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (pimecrolimus + narrowband UVB)
Study: 26037006
Drug: Tablet-based application
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based application and brochure (N=22)
Study: 16025784
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (sleep hygiene)
Study: 7734256
Drug: Continuous systemic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous systemic i.v. butorphanol infusion (83.3 micrograms h‐1)
Study: 7734256
Drug: Continuous brachial
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous brachial plexus infusion of butorphanol (83.3 micrograms h‐1)
Study: 6106785
Drug: Oestrogen supplements
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen supplements
Study: 6106785
Drug: Defaulted from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defaulted from oestrogen therapy
Study: 6106785
Drug: Oestrogen dosage
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen dosage
Study: 28114795
Drug: Lactase dietary
Normalized name: Lactase
DrugBank: Tilactase (DB13761)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactase dietary supplement